文献速递腹部CTMRPET

胰腺癌影像诊断的系统综述与荟萃分析

Imaging-based diagnosis of pancreatic cancer: a systematic review and meta-analysis of direct comparative studies.
PubMed 文献 · Eur Radiol · 2026-10-01

结果显示CT、MRI和EUS检出胰腺癌总体诊断效能无显著差异。MRI检出肝转移的敏感度和特异度更高,而CT在评估血管侵犯和可切除性方面更优。

要点

  • MRI检出肝转移的敏感度和特异度高于CT,潜在根治术前建议加做肝脏MRI以排除小转移灶。
  • CT在血管侵犯评估中优于MRI,且可切除性评估特异度更高,有助于排除不可切除病例。
  • EUS检出淋巴结转移的敏感度高于CT和FDG-PET/CT。

核心结论

  • MRI检出胰腺癌肝转移的汇总敏感度和特异度高于CT,而CT在可切除性评估中的特异度高于MRI。
  • CT、MRI和EUS检出胰腺癌原发灶的诊断效能无显著差异。
  • CT在血管侵犯评估方面优于MRI;EUS检出淋巴结转移的敏感度高于CT或FDG-PET/CT。

研究设计与样本

  • 纳入标准为疑似胰腺癌且至少接受两种影像学检查的直接比较研究;当有病理结果时病理作为参考标准。

关键影像表现/征象

  • MRI在区分肝转移方面显示较高敏感度0.89和特异度0.91。
  • CT在血管侵犯评估中优于MRI。
  • EUS检出淋巴结转移的敏感度高于CT或FDG-PET/CT。

诊断标准与关键数值

  • MRI检出肝转移的敏感度为0.89,95%CI为0.67至0.97;特异度为0.91,95%CI为0.76至0.97。
  • CT检出肝转移的敏感度为0.60,95%CI为0.44至0.74;特异度为0.84,95%CI为0.70至0.93。
  • CT评估可切除性的特异度为0.88,95%CI为0.76至0.94,高于MRI的特异度0.63,95%CI为0.48至0.76。

临床应用与阅片要点

  • 潜在根治性手术前可加做肝脏MRI以排除CT不能发现的小转移灶。
  • CT用于搜索额外转移部位并排除不可切除病例。
  • EUS适合用于术前淋巴结分期评估。

局限性

  • 仅纳入直接比较研究,未报告非直接比较证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is a fast-evolving malignancy, with resection being the only chance of cure. We aim to determine which imaging technique provides the best diagnostic performance in detecting and assessing the spread of PDAC.

MATERIALS AND METHODS: Our study was registered on PROSPERO (CRD42024567008). On July 9, 2024, a systematic search was conducted in three databases, focusing on direct comparative studies that reported on patients suspected of PDAC who underwent at least two imaging methods. When available, the reference test was represented by pathological examinations, and the diagnostic performance of each diagnostic method was assessed. A bivariate model was used to calculate the pooled sensitivity and specificity, along with 95% confidence intervals (CI) for the meta-analysis.

RESULTS: Forty direct comparative studies were eligible for meta-analysis. CT, MRI, and endoscopic ultrasound (EUS) had no significant differences in diagnostic performance for detecting PDAC. MRI showed higher sensitivity [0.89 [0.67-0.97]) and specificity (0.91 [0.76-0.97]) compared to CT (sensitivity 0.60 (CI: 0.44-0.74) and specificity 0.84 [CI: 0.70-0.93]) in distinguishing liver metastases. CT outperformed MRI for vascular invasion assessment. For lymph node detection, EUS proved to have higher sensitivity than CT or FDG-PET/CT. CT had a higher specificity (0.88 [CI: 0.76-0.94]) compared to MRI (0.63 [CI: 0.48-0.76]) when assessing resectability.

CONCLUSION: MRI has a higher pooled sensitivity and specificity for detecting liver metastases of PDAC compared to CT, while the specificity of CT proves to be higher than that of MRI for assessing resectability.

KEY POINTS: QuestionGiven the pancreatic cancer's tight therapeutic window and the need for precise diagnosis, we aim to determine how to best assess it with imaging techniques. FindingsMRI has a significantly higher pooled sensitivity for liver metastases detection than CT. CT has a significantly higher pooled sensitivity for vascular invasion and specificity for resectability assessment than MRI. Clinical relevanceA liver MRI may provide additional value before potentially curative surgery to rule out small metastases. CT should be performed to search for additional metastatic sites and exclude non-resectable cases. Both imaging techniques provide valuable information for assessing pancreatic cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rezuș, Rancz, van Nieuwkerk, et al. Imaging-based diagnosis of pancreatic cancer: a systematic review and meta-analysis of direct comparative studies. Eur Radiol. 2026. PMID: 42821086. doi:10.1007/s00330-026-12890-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。